{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T01:08:47Z","timestamp":1792372127035,"version":"4.4.0"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T00:00:00Z","timestamp":1659657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>For patients with relapsed acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) after allogeneic hematopoietic stem cell transplantation (allo-HSCT), azacitidine with donor lymphocyte infusion (DLI) is a feasible option to perform a preemptive or salvage treatment. However, its efficacy lacked comprehensive analysis, and this study aimed to fill this gap.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We searched potential studies in PUBMED, EMBASE, and the Cochrane Central Register of Controlled Trials. Thirteen studies involving 811 patients were analyzed. The inverse variance method was used to calculate the pooled proportion and 95% confidence interval (CI). Subgroup analysis was performed to explore the source of heterogeneity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The rate of pooled complete remission + partial remission (CR + PR), CR, and 2-year overall survival (OS) were 30% (95% CI: 22%\u201339%), 21% (95% CI: 16%\u201328%), and 31% (95% CI: 27%\u201335%), respectively. The pooled acute graft-versus-host disease (GvHD) and chronic GvHD rates were 15% (95% CI: 9%\u201323%) and 14% (95% CI: 8%\u201323%), respectively. Adverse cytogenetics and a higher percentage of bone marrow (BM) blasts at relapse were correlated with worse CR + PR and CR (interaction p &amp;lt; 0.05). Higher 2-year OS was found in patients with lower BM blasts at relapse or a longer time from allo-HSCT to relapse (interaction p &amp;lt; 0.05). Furthermore, the preemptive treatment for molecular relapse\/minimal residual disease positivity resulted in much better outcomes than that for hematological relapse, both in terms of CR and 2-year OS (interaction p &amp;lt; 0.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The regimen of azacitidine and DLI could safely improve the outcomes of relapsed AML\/MDS after allo-HSCT, especially in those with signs of early relapse. The administration of targeted medicines in azacitidine-based therapies may further improve the outcomes of relapsed AML\/MDS.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.949534","type":"journal-article","created":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T20:46:30Z","timestamp":1659732390000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Azacitidine and donor lymphocyte infusion for patients with relapsed acute myeloid leukemia and myelodysplastic syndromes after allogeneic hematopoietic stem cell transplantation: A meta-analysis"],"prefix":"10.3389","volume":"12","author":[{"given":"Xuefeng","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-06-724500","article-title":"Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel","volume":"129","author":"De Witte","year":"2017","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-01163-z","article-title":"Relapse of acute myeloid leukemia after allogeneic hematopoietic cell transplantation: clinical features and outcomes","volume":"56","author":"Yanada","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1182\/blood-2020-139264","article-title":"Safety and efficacy of salvage therapies for relapse\/refractory AML\/MDS after first allogeneic hematopoietic stem cell transplant: a systematic review","volume":"136","author":"Fatima","year":"2020","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2017.05.010","article-title":"Azacitidine in adult patients with acute myeloid leukemia","volume":"116","author":"Schuh","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0165","article-title":"Oral azacitidine (CC-486) for the treatment of myelodysplastic syndromes and acute myeloid leukemia","volume":"20","author":"Cogle","year":"2015","journal-title":"Oncologist"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.02.003","article-title":"Addition of 10-day decitabine to fludarabine\/total body irradiation conditioning is feasible and induces tumor-associated antigen-specific T cell responses","volume":"22","author":"Cruijsen","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-11-249474","article-title":"Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia","volume":"116","author":"Goodyear","year":"2010","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-11-126227","article-title":"Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse","volume":"112","author":"Kroeger","year":"2008","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13045-017-0416-0","article-title":"Molecular and genetic alterations associated with therapy resistance and relapse of acute myeloid leukemia","volume":"10","author":"Hackl","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V82.8.2310.2310","article-title":"Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose","volume":"82","author":"Drobyski","year":"1993","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.3.513","article-title":"Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation","volume":"11","author":"B\u00e4r","year":"1993","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.03.030","article-title":"Reversal of T cell exhaustion by the first donor lymphocyte infusion is associated with the persistently effective antileukemic responses in patients with relapsed AML after allo-HSCT","volume":"24","author":"Liu","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.6053","article-title":"Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT acute leukemia working party","volume":"25","author":"Schmid","year":"2007","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.63","article-title":"Lymphodepleting chemotherapy with donor lymphocyte infusion post-allogeneic HCT for hematological malignancies is associated with severe, but therapy-responsive aGvHD","volume":"51","author":"He","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-12-257253","article-title":"In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia","volume":"116","author":"Choi","year":"2010","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-210393","article-title":"Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting","volume":"115","author":"S\u00e1nchez-Abarca","year":"2010","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-377044","article-title":"Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)","volume":"119","author":"Goodyear","year":"2012","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting meta-analysis of observational studies in epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040296","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.12.016","article-title":"Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions\u2013a retrospective multicenter analysis from the German cooperative transplant study group","volume":"21","author":"Schroeder","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"D\u00f6hner","year":"2010","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the international working group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.140996","article-title":"Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia","volume":"101","author":"Craddock","year":"2016","journal-title":"Haematologica"},{"key":"B26","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41409-021-01343-5","article-title":"Azacytidine and donor lymphocyte infusions (DLI) as salvage treatment in patients with AML and MDS relapsed after allogeneic stem cell transplantation: a retrospective single center analysis","volume":"56","author":"Aydin","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1605066","article-title":"Managing post allograft relapse of myeloid neoplasms: azacitidine and donor lymphocyte infusions as salvage therapy","volume":"60","author":"Claiborne","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.266","article-title":"5-azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis","volume":"45","author":"Czibere","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"B29","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41409-020-01120-w","article-title":"Azacytidine and donor lymphocytes infusions in relapsed AML after allogeneic HSCT: Results in 40 patients","volume":"55","author":"Liberatore","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.222","article-title":"Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting","volume":"45","author":"L\u00fcbbert","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2017.134","article-title":"Azacitidine and donor lymphocyte infusion in relapsed AML or MDS after allogeneic stem cell transplant. a single centre analysis","volume":"52","author":"Martinez-Cibrian","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01464-x","article-title":"Sequential administration of low dose 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in relapse after allogeneic stem cell transplantation (SCT): a prospective study from the Belgian hematology society (BHS)","volume":"57","author":"Poir\u00e9","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082255","article-title":"Prediction of response and survival following treatment with azacitidine for relapse of acute myeloid leukemia and myelodysplastic syndromes after allogeneic hematopoietic stem cell transplantation","volume":"12","author":"Rautenberg","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.7","article-title":"Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation","volume":"27","author":"Schroeder","year":"2013","journal-title":"Leukemia"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.10","article-title":"5-azacytidine and DLI can induce long-term remissions in AML patients relapsed after allograft","volume":"50","author":"Steinmann","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.10.016","article-title":"Factors determining responses to azacitidine in patients with myelodysplastic syndromes and acute myeloid leukemia with early post-transplantation relapse: a prospective trial","volume":"23","author":"Woo","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2014.116","article-title":"Clinical outcomes of AML patients relapsing after matched-related donor and umbilical cord blood transplantation","volume":"49","author":"Bejanyan","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-08-234492","article-title":"The myth of the second remission of acute leukemia in the adult","volume":"121","author":"Forman","year":"2013","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.2.433","article-title":"Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation","volume":"15","author":"Collins","year":"1997","journal-title":"J Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1808777","article-title":"Immune escape of relapsed AML cells after allogeneic transplantation","volume":"379","author":"Christopher","year":"2018","journal-title":"N Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0400-z","article-title":"Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation","volume":"25","author":"Toffalori","year":"2019","journal-title":"Nat Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.129650","article-title":"Efficacy of immune suppression tapering in treating relapse after reduced intensity allogeneic stem cell transplantation","volume":"100","author":"Kekre","year":"2015","journal-title":"Haematologica"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.7.2322","article-title":"The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial the medical research council adult and children's leukaemia working parties","volume":"92","author":"Grimwade","year":"1998","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11864-019-0612-y","article-title":"Prognostic significance of complex karyotypes in acute myeloid leukemia","volume":"20","author":"Daneshbod","year":"2019","journal-title":"Curr Treat Options Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-375840","article-title":"Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation","volume":"119","author":"Schmid","year":"2012","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2012.12.013","article-title":"Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes","volume":"19","author":"Krishnamurthy","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00889","article-title":"Combination lenalidomide and azacitidine: a novel salvage therapy in patients who relapse after allogeneic stem-cell transplantation for acute myeloid leukemia","volume":"37","author":"Craddock","year":"2019","journal-title":"J Clin Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.22806","article-title":"Clonal evolution of acute myeloid leukemia from diagnosis to relapse","volume":"58","author":"Vosberg","year":"2019","journal-title":"Genes Chromosomes Cancer"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30416-3","article-title":"Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study","volume":"18","author":"Perl","year":"2017","journal-title":"Lancet Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30150-0","article-title":"Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-r): a multicentre, randomised, controlled, open-label, phase 3 trial","volume":"20","author":"Cortes","year":"2019","journal-title":"Lancet Oncol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"key":"B54","doi-asserted-by":"publisher","first-page":"S104","DOI":"10.1016\/j.bbmt.2019.12.608","article-title":"Hypomethylating agents and low-dose venetoclax for relapse acute myeloid leukemia after allogeneic stem cell transplantation","volume":"26","author":"Vigil","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V130.Suppl_1.185.185","article-title":"Checkpoint expression by acute myeloid leukemia (AML) and the immune microenvironment suppresses adaptive immunity","volume":"130","author":"Williams","year":"2017","journal-title":"Blood"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33690","article-title":"A phase 1b\/2 study of azacitidine with PD-L1 antibody avelumab in relapsed\/refractory acute myeloid leukemia","volume":"127","author":"Saxena","year":"2021","journal-title":"Cancer"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0774","article-title":"Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed\/refractory acute myeloid leukemia: a nonrandomized, open-label, phase II study","volume":"9","author":"Daver","year":"2019","journal-title":"Cancer Discovery"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13628","article-title":"Azacitidine for relapse of acute myeloid leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation, multicenter PALG analysis","volume":"107","author":"Drozd-Soko\u0142owska","year":"2021","journal-title":"Eur J Haematol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1002\/acg2.58","article-title":"Azacitidine as salvage therapy for relapsed acute myeloid leukemia\/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation","volume":"2","author":"Ozawa","year":"2019","journal-title":"Adv Cell Gene Ther"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.949534\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T20:46:34Z","timestamp":1659732394000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.949534\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,5]]},"references-count":59,"alternative-id":["10.3389\/fonc.2022.949534"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.949534","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,5]]},"article-number":"949534"}}